Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PSMA (prostate specific membrane antigen) shows promise as a general cancer marker in addition to prostate cancer

This article was originally published in Clinica

Executive Summary

Prostate specific membrane antigen (PSMA) can act as a diagnostic for a wide variety of cancers in addition to prostate cancer, researchers at the Memorial Sloan-Kettering Cancer Center in Princeton, New Jersey have confirmed. However, unlike prostate cancer where it occurs in tumour cells, in these cancers PSMA appears to be associated with the growth of new blood vessels in malignant tissue, lead researcher Dr Sam Chang reports in Cancer Research (July).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT078874

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel